These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Designing multiregional trials under the discrete random effects model. Lan KK; Pinheiro J; Chen F J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977 [TBL] [Abstract][Full Text] [Related]
8. Statistical considerations on design and analysis of bridging and multiregional clinical trials. Tsong Y J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952 [No Abstract] [Full Text] [Related]
9. Sample size determination for a specific region in a multiregional trial. Ko FS; Tsou HH; Liu JP; Hsiao CF J Biopharm Stat; 2010 Jul; 20(4):870-85. PubMed ID: 20496211 [TBL] [Abstract][Full Text] [Related]
10. An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials. Huang Y; Chang WJ; Hsiao CF Pharm Stat; 2013; 12(2):59-64. PubMed ID: 23319408 [TBL] [Abstract][Full Text] [Related]
11. Weighted evidence approach of bridging study. Tsou HH; Tsong Y; Liu JT; Dong X; Wu Y J Biopharm Stat; 2012 Sep; 22(5):952-65. PubMed ID: 22946942 [TBL] [Abstract][Full Text] [Related]
12. Sample size allocation to regions in a multiregional trial. Uesaka H J Biopharm Stat; 2009 Jul; 19(4):580-94. PubMed ID: 20183427 [TBL] [Abstract][Full Text] [Related]
13. Decision rules and associated sample size planning for regional approval utilizing multiregional clinical trials. Chen X; Lu N; Nair R; Xu Y; Kang C; Huang Q; Li N; Chen H J Biopharm Stat; 2012 Sep; 22(5):1001-18. PubMed ID: 22946946 [TBL] [Abstract][Full Text] [Related]
14. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects. Ando Y; Uyama Y J Biopharm Stat; 2012 Sep; 22(5):977-87. PubMed ID: 22946944 [TBL] [Abstract][Full Text] [Related]
15. A Bayesian approach to evaluating regional treatment effect in a multiregional trial. Chen YH; Wu YC; Wang M J Biopharm Stat; 2009 Sep; 19(5):900-15. PubMed ID: 20183451 [TBL] [Abstract][Full Text] [Related]
16. Design and sample size considerations for simultaneous global drug development program. Huang Q; Chen G; Yuan Z; Lan KK J Biopharm Stat; 2012 Sep; 22(5):1060-73. PubMed ID: 22946950 [TBL] [Abstract][Full Text] [Related]
17. Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials. Liu JT; Tsou HH; Gordon Lan KK; Chen CT; Lai YH; Chang WJ; Tzeng CS; Hsiao CF Stat Med; 2016 Jun; 35(14):2301-14. PubMed ID: 26833851 [TBL] [Abstract][Full Text] [Related]
18. Establishing consistency across all regions in a multi-regional clinical trial. Tsou HH; James Hung HM; Chen YM; Huang WS; Chang WJ; Hsiao CF Pharm Stat; 2012; 11(4):295-9. PubMed ID: 22504851 [TBL] [Abstract][Full Text] [Related]
19. Guest editors' note for the special issue on the statistical considerations for the design and analysis of bridging and multiregional clinical trials. Tsong Y; Wang W J Biopharm Stat; 2012 Sep; 22(5):875-8. PubMed ID: 22946936 [No Abstract] [Full Text] [Related]
20. Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials. Wang SJ; James Hung HM J Biopharm Stat; 2012 Sep; 22(5):879-93. PubMed ID: 22946937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]